DrugDashboards

Carboplatin

Carboplatin · CARBOPLATIN 10 mg/mL · Injection · Intravenous · Accord Healthcare, Inc.

NDC 16729-0295-12 · 1 VIAL, MULTI-DOSE in 1 CARTON / 60 mL in 1 VIAL, MULTI-DOSE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. It is in shortage right now — FDA lists the reason as “requirements related to complying with good manufacturing practices”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$3.15per billing unit (50 MG)HCPCS J9045 · Jul 1, 2026
  • Part D plans paid (avg)$1.01per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$47.52
Reported to Texas DSHS · 2026 annual filing · Accord Healthcare, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 50 MG
$3.153
HCPCS J9045 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$98,288
2,777 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $53.36 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA206775
TE code
AP
Approval date
Feb 9, 2017
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)Apr 28, 2023
    Requirements related to complying with good manufacturing practices
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)Apr 28, 2023
    Discontinuation of the manufacture of the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)Apr 28, 2023
    Discontinuation of the manufacture of the drug
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)Apr 28, 2023
    Requirements related to complying with good manufacturing practices
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)Apr 28, 2023
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)Apr 28, 2023
    month 41 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Carboplatin (Injection)

LabelerStrengthFirst seenLast seen
Accord Healthcare, Inc.CARBOPLATIN 10 mg/mLJul 15, 2026Sep 2, 2026
Avyxa Pharma, LLCCARBOPLATIN 500 mg/50mLJul 15, 2026Sep 2, 2026
Avyxa Pharma, LLCCARBOPLATIN 80 mg/8mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Carboplatin — NDC 16729-0295-12," retrieved September 3, 2026, https://drugdashboards.com/drug/16729029512.

Free to cite with attribution — see how the data is put together.